CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED
AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
DEVELOPMENT SUPPLY AGREEMENT
This Development Supply Agreement, effective as of June 22, 2005 (the “Effective Date”), is made by and between ****
(hereinafter ****) and Antares Pharma AG, having its principal offices at Geweberstrasse 18, 4123 Allschwil, Switzerland
Antares is in the business of marketing branded pharmaceutical products and has developed an orally disintegrating version of
**** (“Product”). Antares desires to have **** develop a manufacturing and testing protocol for the Product and to
manufacture quantities of the Product for use in testing to support Antares’ regulatory filing. **** is engaged in the business
of commercial manufacturing, formulating and developing pharmaceutical products in finished dosage form. The parties wish to
enter into this Agreement to have **** develop and manufacture the Product according to the terms and conditions of this
NOW, THEREFORE , in view of this foregoing premise and in consideration of the foregoing premises and in consideration of
the mutual covenants set forth below, the parties agree as follows:
For the purposes of this Agreement, the following terms shall have the following respective meanings:
1.1 "Development Program" shall mean the program outlined in Appendix 1 hereto.
1.2 “**** Development Activities” shall mean the activities for which **** has agreed to be responsible in the Development
1.3 “Formulation” shall mean the orally disintegrating tablet formulations developed hereunder and the protocols, batch
records and all other relevant manufacturing information regarding the same.
1.4 "Product" shall mean an orally disintegrating version of the **** oral tablet.
1.5 “Specifications” means those protocols and standard operating procedures, including withou